IOVANCE BIOTHERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $49.57M, a 279.33% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $98.51M, a 33.86% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $88.52M, a 86.28% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $13.07M, a 91.43% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $463.28M, a 144.47% increase from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2022 was $189.50M, a 6.72% decline from fiscal 2021.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2021 was $203.16M, a 64.17% decline from fiscal 2020.
- IOVANCE BIOTHERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2020 was $567.04M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $49.57M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $98.51M 10-Q · filed 2026-05-07 | |
| 2025-09-30 | $88.52M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $13.07M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $148.94M 10-Q · filed 2026-05-07 | |
| 2024-09-30 | $47.52M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $152.43M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $197.36M 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $463.28M 10-K · filed 2024-02-28 | |
| 2023-09-30 | $203.18M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $260.10M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $189.50M 10-K · filed 2023-02-28 | |
| 2021-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $203.16M 10-K · filed 2023-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $203.16M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $160.27M 10-Q · filed 2022-08-04 | $203.20M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $42.88M 10-Q · filed 2022-05-05 | $609.93M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $567.04M 10-K · filed 2023-02-28 |
| 2020-09-30 | $43.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $567.00M 10-Q · filed 2021-08-05 | |
| 2018-12-31 | $236.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $398.82M 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | |
| 2018-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | |
| 2018-03-31 | $162.09M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $53.66M 10-K · filed 2020-02-25 | |
| 2015-12-31 | $68.31M 10-K · filed 2018-03-12 | |
| 2012-03-31 | $67.92K 10-Q · filed 2012-05-15 | |
| 2007-12-31 | $8.00K 10-K · filed 2013-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |